Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2018 | Correction

Correction to: Serum DNA integrity index as a potential molecular biomarker in endometrial cancer

Authors: Enrico Vizza, Giacomo Corrado, Martina De Angeli, Mariantonia Carosi, Emanuela Mancini, Ermelinda Baiocco, Benito Chiofalo, Lodovico Patrizi, Ashanti Zampa, Giulia Piaggio, Lucia Cicchillitti

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2018

Excerpt

In the publication of this article [1], there is an error in the first sentence of the Acknowledgements section. …

Vizza E, Corrado G, De Angeli M, et al. Serum DNA integrity index as a potential molecular biomarker in endometrial cancer. J Exp Clin Cancer Res. 2018;37(1):16. https://doi.org/10.1186/s13046-018-0688-4.CrossRefPubMedPubMedCentral

Title: Correction to: Serum DNA integrity index as a potential molecular biomarker in endometrial cancer
Authors: Enrico Vizza
Giacomo Corrado
Martina De Angeli
Mariantonia Carosi
Emanuela Mancini
Ermelinda Baiocco
Benito Chiofalo
Lodovico Patrizi
Ashanti Zampa
Giulia Piaggio
Lucia Cicchillitti
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2018
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-018-0708-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

KPNA2 promotes metabolic reprogramming in glioblastomas by regulation of c-myc

HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways

miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway

MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma

Paired box 8 suppresses tumor angiogenesis and metastasis in gastric cancer through repression of FOXM1 via induction of microRNA-612

The plant alkaloid tetrandrine inhibits metastasis via autophagy-dependent Wnt/β-catenin and metastatic tumor antigen 1 signaling in human liver cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer